Tagged as: 23andme, biology, Brad, bradley, bradley miller, breast cancer, Cancer, clinical, clinical diagnostics, congress, data, data set, dna, genetic, genetic testing, genetics, Medicine, medicinethink, miller, nature, perspective, san francisco, testing
23andme + Genetic Testing = Consumer Engagement
Previous post: UK Election Day
Next post: Passion Fundamentals – the Drive Inside
{ 2 comments… read them below or add one }
With yesterday’s announcement that Walgreens is offering the The Insight kit from Pathway Genomics for around $250, your blog couldn’t have been more timely… Your thoughts above are similar to those discussed in the Decision Tree (http://thedecisiontree.com/blog/) in patients are able to collect so many more data points and our ability to correlate these with outcomes will potentially change how we monitor drug safety and other disease outcomes over time with these increased data points.
Thanks, enjoyed your blog…if you follow me on twitter, we can continue the sharing of information….Cheers!
The Insight Genomics announcement was a nice coincidence, indeed! The one thing I’d say toTom’s comment is that correlating gene data to outcome data will be important – but that will require even more work and stickyness on 23andme’s part. However, collecting phenotypic data along with the genomic data – that will allow for pretty powerful science as well in the future.